Medical director and principal investigator Prof. Marco van Vulpen about his research focus:
“We are facing a paradigm shift in radiotherapy, moving from ‘elective’ to an ‘ablative’, more surgical-like, approach, with fewer treatment fractions. This is enabled by on-board imaging with optimal contrast between tumor and normal tissues, online AI-based contouring, online treatment planning and decision loops to enable a daily new treatment plan. Several innovations that enable such a tailored and personalized approach are clinically introduced, like the MRI-linac and proton therapy with advanced on-board CT. Here, the patient especially benefits.”